Genetic Variation in the Transporters and Hypoglycemic Agents

Ajou University School of Medicine

Status: Unknown

Conditions: Type 2 Diabetes

Study type: Observational

Funder types: Other

Identifiers

NCT01341795

GDM01

Details and patient eligibility

About

Type 2 diabetes have become a major global health problem. Currently, metformin is used as first-line therapy in combination with lifestyle changes, and sitagliptin can be added to metformin in case of insufficient glycemic control by metformin alone, and fixed-dose combination of sitagliptin and metformin is available.

In clinical practice, inter-individual variations in response to sitagliptin and metformin treatment are commonly found, which may reflect inter-patient differences in disposition of these medications.

Sitagliptin and metformin are known as substrates of some transporters (P-gp, OAT3, OCT1 and OCT2) and some functional variations of these transporters were reported. This study is designed to clarify the effect of these transporter variants on response to sitagliptin and metformin in type 2 DM patients.

Enrollment: 100 estimated patients

Sex: All

Ages: 20 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Newly Diagnosed Type 2 Diabetes Patients
• 20-80 years old
• Taking sitagliptin and metformin for more than 3 months

Exclusion criteria

• Taking other oral hypoglycemic agents
• Taking medications can induce or inhibit transporters